Skip to main content

18-10-2019 | Rheumatology | News | Article


Upadacitinib recommended for European approval

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended approval of upadacitinib for the treatment of rheumatoid arthritis (RA).

The selective Janus kinase 1 inhibitor is recommended, either alone or in combination with methotrexate, for the treatment of adult patients with moderate-to-severe RA and an inadequate response or intolerance to at least one DMARD. It will be available as 15 mg prolonged-release tablets.

This announcement follows approval of upadacitinib for RA by the US FDA in August 2019.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group